Choose appropriate advanced cancer patients with Claudin6 expression, with written consent for the study;~Perform PBMCs apheresis from the patient and isolate NK cells, transfect the NK cells with Claudin6 targeting CAR, amplify the number of transfected NK cells as needed, test the quality and killing activity of the Claudin6-CAR-NK cells and then transplant back the patients via systemic or local infusions (via artery or intra-tumor), and follow up closely to collect related results as needed;~To enhance the killing capability, some CAR-NK cells are genetically engineered to express and secret IL7/CCL19 and/or SCFVs against PD1/CTLA4/Lag3;~Evaluate the clinical results as needed.~Will also perform the similar clinical trial on different cancer types with Claudin6 expression.
This study is a single-arm, open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6 targeting CAR-NK cells in patients with Claudin6-positive advanced solid tumors (ovarian cancer and others)